| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
79,620,000 |
| Market
Cap: |
12.77(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1604 - $0.1604 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare diseases. Co.'s primary candidate is Diazoxide Choline Extended Release tablets (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
343,298 |
343,298 |
| Total Buy Value |
$0 |
$0 |
$1,897,756 |
$1,897,756 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
12 |
12 |
| Total Shares Sold |
1,129,833 |
1,419,857 |
1,419,857 |
2,030,451 |
| Total Sell Value |
$52,883,521 |
$62,474,611 |
$62,474,611 |
$63,437,018 |
| Total People Sold |
5 |
5 |
5 |
6 |
| Total Sell Transactions |
6 |
27 |
27 |
76 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Anish Bhatnagar |
Chief Executive Officer |
• • – |
2023-11-29 |
4 |
S |
$27.43 |
$774,535 |
D/D |
(27,827) |
135,778 |
|
- |
|
| Yen Kristen |
See Remarks |
• – – |
2023-11-29 |
4 |
S |
$27.43 |
$110,751 |
D/D |
(3,979) |
25,913 |
|
- |
|
| Mackaness James H |
Chief Financial Officer |
• – – |
2023-11-29 |
4 |
S |
$27.43 |
$116,986 |
D/D |
(4,203) |
25,489 |
|
- |
|
| Hirano Patricia C |
See Remarks |
• – – |
2023-11-29 |
4 |
S |
$27.43 |
$106,855 |
D/D |
(3,839) |
30,041 |
|
- |
|
| Anish Bhatnagar |
Chief Executive Officer |
• • – |
2023-11-28 |
4 |
S |
$27.03 |
$696,514 |
D/D |
(25,678) |
163,605 |
|
- |
|
| Yen Kristen |
See Remarks |
• – – |
2023-11-28 |
4 |
S |
$27.03 |
$99,575 |
D/D |
(3,671) |
29,892 |
|
- |
|
| Mackaness James H |
Chief Financial Officer |
• – – |
2023-11-28 |
4 |
S |
$27.03 |
$105,190 |
D/D |
(3,878) |
29,692 |
|
- |
|
| Hirano Patricia C |
See Remarks |
• – – |
2023-11-28 |
4 |
S |
$27.03 |
$96,076 |
D/D |
(3,542) |
33,880 |
|
- |
|
| Anish Bhatnagar |
Chief Executive Officer |
• • – |
2023-10-20 |
4 |
OE |
$1.75 |
$30,500 |
D/D |
9,643 |
198,926 |
|
- |
|
| Mackaness James H |
Chief Financial Officer |
• – – |
2023-10-02 |
4 |
OE |
$1.75 |
$24,497 |
D/D |
8,309 |
41,879 |
|
- |
|
| Vivo Opportunity Fund Holdings, L.p. |
10% Owner |
– – • |
2023-10-02 |
4 |
OE |
$2.50 |
$13,037,500 |
I/I |
5,215,000 |
8,418,093 |
|
- |
|
| Abingworth Bioventures Vii Lp |
10% Owner |
– – • |
2023-09-28 |
4 |
OE |
$1.75 |
$577,378 |
I/I |
329,930 |
1,531,436 |
|
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-06-06 |
4 |
B |
$5.93 |
$1,186 |
I/I |
200 |
2,207,753 |
1.42 |
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-06-05 |
4 |
B |
$5.98 |
$469,239 |
I/I |
78,468 |
2,207,553 |
1.5 |
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-06-02 |
4 |
B |
$5.93 |
$383,256 |
I/I |
64,630 |
2,129,085 |
1.5 |
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-06-01 |
4 |
B |
$5.59 |
$41,925 |
I/I |
7,500 |
2,064,455 |
1.5 |
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-05-31 |
4 |
B |
$5.28 |
$52,800 |
I/I |
10,000 |
2,056,955 |
1.5 |
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-05-30 |
4 |
B |
$5.34 |
$93,450 |
I/I |
17,500 |
2,046,955 |
1.5 |
- |
|
| Mackaness James H |
Chief Financial Officer |
• – – |
2023-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
29,084 |
33,570 |
|
- |
|
| Anish Bhatnagar |
Chief Executive Officer |
• • – |
2023-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
160,602 |
189,283 |
|
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-05-26 |
4 |
B |
$5.27 |
$118,575 |
I/I |
22,500 |
2,029,455 |
1.5 |
- |
|
| Hirano Patricia C |
See Remarks |
• – – |
2023-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
28,149 |
37,422 |
|
- |
|
| Yen Kristen |
See Remarks |
• – – |
2023-05-26 |
4 |
A |
$0.00 |
$0 |
D/D |
29,131 |
33,563 |
|
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-05-25 |
4 |
B |
$5.18 |
$194,250 |
I/I |
37,500 |
2,006,955 |
1.5 |
- |
|
| Edelman Joseph |
10% Owner |
– – • |
2023-05-24 |
4 |
B |
$5.48 |
$137,000 |
I/I |
25,000 |
1,969,455 |
1.5 |
- |
|
386 Records found
|
|
Page 2 of 16 |
|
|
